MENU
SEP 16, 2020 11:00 AM | SEPT 17, 11:00 AM SGT | SEPT 17, 4:00 PM CEST

How to Limit Patient Harm from Erroneous Results, QC Strategies Based on Risk Management

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Scientific Fellow, Bio-Rad Laboratories
    Biography

      Mr. Yundt-Pacheco performs research in quality control and patient risk issues in the Informatics Discovery Group at Bio-Rad. John has had the opportunity to work with laboratories around the world, developing practical real time, inter-laboratory quality control and proficiency testing systems. As an innovator, has developed numerous ideas leading to 37 laboratory related invention patents around the globe.



      John holds a Master’s degree in Computer Science from University of Texas at Dallas with a focus on Intelligent Systems and has a Post Master’s Certificate in Sequence Analysis and Genomics, and is a degree candidate for a Master’s degree in Biotechnology at Johns Hopkins University. In addition to authoring articles and papers on QC design, he is a popular speaker on laboratory QC and QA topics at international conferences.


    Abstract

    Quality Control design has for many years been focused around instrument performance. But with the new risk management approaches emerging the focus is now moving to the risk of erroneous results for patients. This presentation will describe this new approach designed to prevent patient harm from erroneous results to acceptable levels.

    Learning Objectives:
    1. Identify the steps in patient risk managed QC strategy design.
    2. Explain how to set the Severity of Harm category for an analyte.
    3. Describe 2 components of the QC design that can be changed to minimize patient risk.


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more